Category: Cancer (page 4 of 5)

dioxin causes reproductive problems

2,3,7,8-Tetrachlorodibenzo-p-dioxin, referred to as dioxin, is a contaminant in Agent Orange. It is toxic and known to cause developmental defects and cancer.

From Science Daily:

 Since the 1960s, when the defoliant Agent Orange was widely used in Vietnam, military, industry and environmental groups have debated the toxicity of one of its ingredients, the chemical dioxin, and how it should be regulated.

But even if all the dioxin were eliminated from the planet, Washington State University researchers say its legacy would live on in the way it turns genes on and off in the descendants of people exposed over the past half century.

Writing in the journal PLoS ONE, biologist Michael Skinner and members of his lab say dioxin administered to pregnant rats resulted in a variety of reproductive problems and disease in subsequent generations. The first generation of rats had prostate disease, polycystic ovarian disease and fewer ovarian follicles, the structures that contain eggs. To the surprise of Skinner and his colleagues, the third generation had even more dramatic incidences of ovarian disease and, in males, kidney disease.

“Therefore, it is not just the individuals exposed, but potentially the great-grandchildren that may experience increased adult-onset disease susceptibility,” says Skinner.

are we near drug treatments for lung cancer?

Exciting news from the New York Times regarding drug treatments for certain lung cancers:

The first large and comprehensive study of the genetics of a common lung cancer has found that more than half the tumors from that cancer have mutations that might be treated by new drugs that are already in the pipeline or that could be easily developed.

For the tens of thousands of Americans with that cancer — squamous cell lung cancer — the results are promising because they could foretell a new type of treatment in which drugs are tailored to match the genetic abnormality in each patient, researchers say.

“This is a disease where there are no targeted therapies,” said Dr. Matthew Meyerson of the Dana-Farber Cancer Institute in Boston, referring to modern drugs that attack genetic abnormalities. He is a lead author of a paper on the study, with more than 300 authors, which was published online in the journal Nature on Sunday.

“What we found will change the landscape for squamous cell carcinoma,” Dr. Meyerson said. “I think it gives hope to patients.”

The study is part of the Cancer Genome Atlas, a large project by the National Institutes of Healthto examine genetic abnormalities in cancer.

Read the original Nature paper here.

new adrogen blocking drug approved for prostate cancer

From Elie Dolgin of Nature magazine covers the news:

Men with advanced prostate cancer now have another treatment option, thanks to the approval today by the US Food and Drug Administration (FDA) of a pill that blocks androgen-receptor signaling and prolongs patient survival.

“To see activity in a post-hormone treated, post-chemotherapy treated prostate cancer population with a drug that doesn’t have myelosuppression [a decrease in blood cell production] and does has a very favorable safety profile is extremely exciting,” says Howard Scher, a prostate cancer specialist at the Memorial Sloan-KetteringCancer Center in New York. “My patient who got the drug in July 2007 is still on it. I have chills actually. It’s pretty amazing.”

The newly approved agent—Xtandi (enzalutamide), developed by San Francisco’s Medivation and Japan’s Astellas Pharma—works by plugging up the receptors that bind androgens, including testosterone, to prevent those male hormones from fueling the growth of prostate cancer cells. In a phase 3 clinical trial involving around 1,200 men with prostate cancer that had spread despite prior chemo- and hormone-therapy, an international team led by Scher found that participants taking Xtandi lived a median of 18.4 months, compared to 13.6 months for those who received a placebo. The drug also significantly lowered levels of prostate-specific antigen and boosted the time of progression-free survival, with only minimal side effects of fatigue, diarrhea and rare seizures. The results were reported earlier this month in the New England Journal of Medicine.

Read the complete coverage here.

//cuboulrus.net/4/4535925